Strata Critical Medical (SRTA) Current Deferred Revenue (2019 - 2025)

Strata Critical Medical (SRTA) has 7 years of Current Deferred Revenue data on file, last reported at $9.1 million in Q2 2025.

• Current Deferred Revenue for Q2 2025 came in at $9.1 million, down 1.66% year-over-year; the trailing twelve-month figure through Jun 2025 was $9.1 million (down 1.66% YoY), and the FY2024 annual result was $6.7 million, down 2.76% from the prior year.
• Current Deferred Revenue climbed to $9.1 million in Q2 2025 per SRTA's latest filing, from $8.0 million in the prior quarter.
• Over five years, Current Deferred Revenue peaked at $10.0 million in Q2 2023 and troughed at $4.4 million in Q1 2021.
• A 5-year average of $7.1 million and a median of $6.8 million in 2022 frame the typical range for Current Deferred Revenue.
• The sharpest annual moves came in 2022 and 2024: Current Deferred Revenue soared 61.41% in 2022, then decreased 7.47% in 2024.
• A 5-year view of Current Deferred Revenue shows it stood at $6.0 million in 2021, then climbed by 12.27% to $6.7 million in 2022, then rose by 2.03% to $6.8 million in 2023, then fell by 2.76% to $6.7 million in 2024, then surged by 36.9% to $9.1 million in 2025.
• Business Quant data shows SRTA's Current Deferred Revenue at $9.1 million in Q2 2025, $8.0 million in Q1 2025, and $6.7 million in Q4 2024.